{
  "schema_version": "1.0",
  "type": "article",
  "title": "ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload",
  "url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.md",
  "lang": "zh-Hant",
  "date": "2026-07-14",
  "publish_at": "2026-07-14T08:00:00+08:00",
  "updated_at": "2026-07-14",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "商業分析系列",
    "ADC",
    "Novartis",
    "Myricx Bio",
    "NMTi",
    "payload",
    "BD 授權",
    "腫瘤",
    "浩鼎",
    "諦醫生技",
    "嘉正生技"
  ],
  "summary": "諾華最高 15 億美元收購 Myricx，真正買下的不只是兩條 ADC 管線，而是可能改寫安全窗、耐藥與平台估值的新型 NMTi payload。",
  "key_points": [],
  "facts": [],
  "sections": [
    "01｜ADC 的老問題：好靶點不等於好藥",
    "02｜NMTi-ADC：諾華買的是一種新的殺傷邏輯",
    "03｜諾華的 ADC 態度：等到差異化才下手",
    "04｜風險：payload 新，不代表臨床一定贏",
    "05｜台灣怎麼看：浩鼎、諦醫、嘉正，要問三種問題",
    "結語｜ADC 不缺下一個跟隨者，缺下一種答案",
    "參考資料",
    "免責聲明"
  ],
  "references": [
    {
      "title": "[Novartis",
      "source": "Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload]",
      "date": "",
      "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients"
    },
    {
      "title": "[OBI Pharma",
      "source": "Pipeline Overview]",
      "date": "",
      "url": "https://www.obipharma.com/what-we-do/pipeline-overview/"
    },
    {
      "title": "[OBI Pharma",
      "source": "Obrion ADC Technology Platform]",
      "date": "",
      "url": "https://www.obipharma.com/what-we-do/technology-platform/"
    },
    {
      "title": "[免疫功坊",
      "source": "賀！諦醫生技入圍世界ADC獎，技術平台與產品獲國際肯定]",
      "date": "",
      "url": "https://immunwork.com/article_d.php?lang=tw&tb=4&id=1524"
    }
  ],
  "images": [
    {
      "alt": "ADC 下一場競爭將從熱門靶點推進到 payload、安全窗、耐藥與平台可複製性的綜合比較",
      "url": "https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-01.webp"
    },
    {
      "alt": "下一代 ADC 必須同時回答靶點、linker、payload、安全窗、耐藥與平台延伸能力",
      "url": "https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-02.webp"
    },
    {
      "alt": "NMTi-ADC 透過抗體將新型 payload 送入腫瘤細胞並干擾關鍵細胞功能依賴",
      "url": "https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-03.webp"
    },
    {
      "alt": "台灣 ADC 公司要分別從公開管線、技術進臨床與資料透明度三條證據線觀察",
      "url": "https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-04.webp"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-07-14）。ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload。https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {
    "en": "2026-07-14-novartis-myricx-nmti-adc-en.html"
  }
}